The Function of Matricellular Proteins in the Lamina Cribrosa and Trabecular Meshwork in Glaucoma

Journal of Ocular Pharmacology and Therapeutics

Volumn 31, Issue 7, 2015, Pages 386-395

  Wallace, Deborah M ^a,b   Pokrovskaya, Olya ^a,b   O'Brien, Colm J ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; GLYCOPROTEIN; OSTEONECTIN; TENASCIN; TENASCIN X; THROMBOSPONDIN; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; SCLEROPROTEIN;

ARTICLE; EXTRACELLULAR MATRIX; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LAMINA CRIBROSA; NONHUMAN; OPTIC DISK CUP; OPTIC NERVE; OPTIC NERVE HEAD; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRABECULAR MESHWORK; VISUAL FIELD DEFECT; VISUAL NERVOUS SYSTEM; ANIMAL; METABOLISM; OPTIC DISK; PATHOLOGY;

ANIMALS; EXTRACELLULAR MATRIX PROTEINS; GLAUCOMA; HUMANS; OPTIC DISK; TRABECULAR MESHWORK;

EID: 84941208516     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2014.0163     Document Type: Article

References (162)

1. Quigley, H.A., and Broman, A.T. The number of people with glaucom worldwide in 2010 and 2020. Br. J. Ophthalmol. 90:262-267, 2006.
2. Kelliher, C., Kenny, D., and O'Brien C. Trends in blind registration in the adult population of the Republic of Ireland 1996-2003. Br. J. Ophthalmol. 90:367-371, 2006.
3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126:487-497, 1998.
4. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am. J. Ophthalmol. 126:498-505, 1998.
5. Spry, P.G., Sparrow, J.M., Diamond, J.P., and Harris, H.S. Risk factors for progressive visual field loss in primary open angle glaucoma. Eye (Lond). 19:643-651, 2005.
6. Gordon, M.O., Beiser, J.A., Brandt, J.D., et al. The ocular hypertension treatment study: baseline factors that predict the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:714-720; discussion 829-830, 2002.
7. Leske, M.C., Heijl, A., Hyman, L., Bengtsson, B., and Komaroff, E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr. Opin. Ophthalmol. 15:102-106, 2004.
8. Tamm, E.R. The trabecular meshwork outflow pathways: structural and functional aspects. Exp. Eye Res. 88:648-655, 2009.
9. Maepea, O., and Bill, A. Pressures in the juxtacanalicular tissue and Schlemm's canal in monkeys. Exp. Eye Res. 54:879-883, 1992.
10. Moses, R.A. The effect of intraocular pressure on resistance to outflow. Surv. Ophthalmol. 22:88-100, 1977.
11. Johnson, M., Chan, D., Read, A.T., Christensen, C., Sit, A., and Ethier, C.R. The pore density in the inner wall endothelium of Schlemm's canal of glaucomatous eyes. Invest. Ophthalmol. Vis. Sci. 43:2950-2955, 2002.
12. Johnson, M. What controls aqueous humour outflow resistance? Exp. Eye Res. 82:545-557, 2006.
13. Ethier, C.R., Kamm, R.D., Palaszewski, B.A., Johnson, M.C., and Richardson, T.M. Calculations of flow resistance in the juxtacanalicular meshwork. Invest. Ophthalmol. Vis. Sci. 27:1741-1750, 1986.
14. Acott, T.S., and Kelley, M.J. Extracellular matrix in the trabecular meshwork. Exp. Eye Res. 86:543-561, 2008.
15. Tian, B., Geiger, B., Epstein, D.L., and Kaufman, P.L. Cytoskeletal involvement in the regulation of aqueous humor outflow. Invest. Ophthalmol. Vis. Sci. 41:619-623, 2000.
16. Epstein, D.L., Freddo, T.F., Bassett-Chu, S., Chung, M., and Karageuzian, L. Influence of ethacrynic acid on outflow facility in the monkey and calf eye. Invest. Ophthalmol. Vis. Sci. 28:2067-2075, 1987.
17. Epstein, D.L., Rowlette, L.L., and Roberts, B.C. Actomyosin drug effects and aqueous outflow function. Invest. Ophthalmol. Vis. Sci. 40:74-81, 1999.
18. Wiederholt, M., Thieme, H., and Stumpff, F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog. Retin. Eye Res. 19:271-295, 2000.
19. Rao, P.V., Deng, P., Sasaki, Y., and Epstein, D.L. Regulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facility. Exp. Eye Res. 80:197-206, 2005.
20. Tian, B., and Kaufman, P.L. Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp. Eye Res. 80:215-225, 2005.
21. Yu, M., Chen, X., Wang, N., et al. H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes. J. Ocul. Pharmacol. Ther. 24:373-379, 2008.
22. Zhou, E.H., Krishnan, R., Stamer, W.D., et al. Mechanical responsiveness of the endothelial cell of Schlemm's canal: scope, variability and its potential role in controlling aqueous humour outflow. J. R. Soc. Interface 9:1144-1155, 2012.
23. Overby, D.R., Zhou, E.H., Vargas-Pinto, R., et al. Altered mechanobiology of Schlemm's canal endothelial cells in glaucoma. Proc. Natl. Acad. Sci. U S A. 111:13876-13881, 2014.
24. Zhang, M., Maddala, R., and Rao, P.V. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am. J. Physiol. Cell Physiol. 295:C1057-C1070, 2008.
25. Honjo, M., Tanihara, H., Inatani, M., et al. Effects of rhoassociated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest. Ophthalmol. Vis. Sci. 42:137-144, 2001.
26. Yang, H., Thompson, H., Roberts, M.D., Sigal, I.A., Downs, J.C., and Burgoyne, C.F. Deformation of the early glaucomatous monkey optic nerve head connective tissue after acute IOP elevation in 3-D histomorphometric reconstructions. Invest. Ophthalmol. Vis. Sci. 52:345-363, 2011.
27. Yang, H., Williams, G., Downs, J.C., et al. Posterior (outward) migration of the lamina cribrosa and early cupping in monkey experimental glaucoma. Invest. Ophthalmol. Vis. Sci. 52:7109-7121, 2011.
28. Jonas, J.B., Berenshtein, E., and Holbach, L. Anatomic relationship between lamina cribrosa, intraocular space, and cerebrospinal fluid space. Invest. Ophthalmol. Vis. Sci. 44:5189-5195, 2003.
29. Burgoyne, C.F., Downs, J.C., Bellezza, A.J., Suh, J.K., and Hart, R.T. The optic nerve head as a biomechanical structure: a new paradigm for understanding the role of IOP-related stress and strain in the pathophysiology of glaucomatous optic nerve head damage. Prog. Retin. Eye Res. 24:39-73, 2005.
30. Hernandez, M.R., and Pena, J.D. The optic nerve head in glaucomatous optic neuropathy. Arch. Ophthalmol. 115: 389-395, 1997.
31. Hernandez, M.R., Andrzejewska, W.M., and Neufeld, A.H. Changes in the extracellular matrix of the human optic nerve head in primary open-angle glaucoma. Am. J. Ophthalmol. 109:180-188, 1990.
32. Steely, H.T., Jr., English-Wright, S.L., and Clark, A.F. The similarity of protein expression in trabecular meshwork and lamina cribrosa: implications for glaucoma. Exp. Eye Res. 70:17-30, 2000.
33. Rehnberg, M., Ammitzboll, T., and Tengroth, B. Collagen distribution in the lamina cribrosa and the trabecular meshwork of the human eye. Br. J. Ophthalmol. 71:886-892, 1987.
34. Hernandez, M.R., Weinstein, B.I., Schwartz, J., Ritch, R., Gordon, G.G., and Southren, A.L. Human trabecular meshwork cells in culture: morphology and extracellular matrix components. Invest. Ophthalmol. Vis. Sci. 28:1655-1660, 1987.
35. Morrison, J.C., L'Hernault, N.L., Jerdan, J.A., and Quigley, H.A. Ultrastructural location of extracellular matrix components in the optic nerve head. Arch. Ophthalmol. 107:123-129, 1989.
36. Yun, A.J., Murphy, C.G., Polansky, J.R., Newsome, D.A., and Alvarado, J.A. Proteins secreted by human trabecular cells. Glucocorticoid and other effects. Invest. Ophthalmol. Vis. Sci. 30:2012-2022, 1989.
37. Clark, A.F., Wilson, K., McCartney, M.D., Miggans, S.T., Kunkle, M., and Howe, W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 35:281-294, 1994.
38. Wilson, K., McCartney, M.D., Miggans, S.T., and Clark, A.F. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr. Eye Res. 12:783-793, 1993.
39. Kirwan, R.P., Wordinger, R.J., Clark, A.F., and O'Brien, C.J. Differential global and extra-cellular matrix focused gene expression patterns between normal and glaucomatous human lamina cribrosa cells. Mol. Vis. 15:76-88, 2009.
40. Hann, C.R., Springett, M.J., Wang, X., and Johnson, D.H. Ultrastructural localization of collagen IV, fibronectin, and laminin in the trabecular meshwork of normal and glaucomatous eyes. Ophthalmic Res. 33:314-324, 2001.
41. Tektas, O.Y., and Lutjen-Drecoll, E. Structural changes of the trabecular meshwork in different kinds of glaucoma. Exp. Eye Res. 88:769-775, 2009.
42. Anderson, D.R. Ultrastructure of human and monkey lamina cribrosa and optic nerve head. Arch. Ophthalmol. 82:800-814, 1969.
43. Hernandez, M.R., Igoe, F., and Neufeld, A.H. Cell culture of the human lamina cribrosa. Invest. Ophthalmol. Vis. Sci. 29:78-89, 1988.
44. Quigley, H.A. Glaucoma. Lancet 377:1367-1377, 2011.
45. Ozbek, S., Balasubramanian, P.G., Chiquet-Ehrismann, R., Tucker, R.P., and Adams, J.C. The evolution of extracellular matrix. Mol. Biol. Cell 21:4300-4305, 2010.
46. De Groef, L., Van Hove, I., Dekeyster, E., Stalmans, I., and Moons, L. MMPs in the trabecular meshwork: promising targets for future glaucoma therapies? Invest. Ophthalmol. Vis. Sci. 54:7756-7763, 2013.
47. Okada, Y., Gonoji, Y., Nakanishi, I., Nagase, H., and Hayakawa, T. Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 59:305-312, 1990.
48. Woessner, J.F., Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5:2145-2154, 1991.
49. Backstrom, J.R., Miller, C.A., and Tokes, Z.A. Characterization of neutral proteinases from Alzheimeraffected and control brain specimens: identification of calcium-dependent metalloproteinases from the hippocampus. J. Neurochem. 58:983-992, 1992.
50. Giraudon, P., Buart, S., Bernard, A., Thomasset, N., and Belin, M.F. Extracellular matrix-remodeling metalloproteinases and infection of the central nervous system with retrovirus human T-lymphotropic virus type I (HTLV-I). Prog. Neurobiol. 49:169-184, 1996.
51. Yan, X., Tezel, G., Wax, M.B., and Edward, D.P. Matrix metalloproteinases and tumor necrosis factor alpha in glaucomatous optic nerve head. Arch. Ophthalmol. 118:666-673, 2000.
52. Yuan, L., and Neufeld, A.H. Activated microglia in the human glaucomatous optic nerve head. J. Neurosci. Res. 64:523-532, 2001.
53. Kirwan, R.P., Crean, J.K., Fenerty, C.H., Clark, A.F., and O'Brien, C.J. Effect of cyclical mechanical stretch and exogenous transforming growth factor-beta1 on matrix metalloproteinase-2 activity in lamina cribrosa cells from the human optic nerve head. J. Glaucoma 13:327-334, 2004.
54. Alexander, J.P., Samples, J.R., Van Buskirk, E.M., and Acott, T.S. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 32:172-180, 1991.
55. Kelley, M.J., Rose, A.Y., Song, K., et al. Synergism of TNF and IL-1 in the induction of matrix metalloproteinase-3 in trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 48:2634-2643, 2007.
56. Oh, D.J., Martin, J.L., Williams, A.J., Russell, P., Birk, D.E., and Rhee, D.J. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 47:3887-3895, 2006.
57. Bradley, J.M., Kelley, M.J., Zhu, X., Anderssohn, A.M., Alexander, J.P., and Acott, T.S. Effects of mechanical stretching on trabecular matrix metalloproteinases. Invest. Ophthalmol. Vis. Sci. 42:1505-1513, 2001.
58. Bradley, J.M., Vranka, J., Colvis, C.M., et al. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 39: 2649-2658, 1998.
59. Fleenor, D.L., Pang, I.H., and Clark, A.F. Involvement of AP-1 in interleukin-1alpha-stimulated MMP-3 expression in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 44:3494-3501, 2003.
60. Gonzalez, P., Epstein, D.L., and Borras, T. Genes upregulated in the human trabecular meshwork in response to elevated intraocular pressure. Invest. Ophthalmol. Vis. Sci. 41:352-361, 2000.
61. Luna, C., Li, G., Liton, P.B., Epstein, D.L., and Gonzalez, P. Alterations in gene expression induced by cyclic mechanical stress in trabecular meshwork cells. Mol. Vis. 15:534-544, 2009.
62. Vittitow, J., and Borras, T. Genes expressed in the human trabecular meshwork during pressure-induced homeostatic response. J. Cell Physiol. 201:126-137, 2004.
63. WuDunn, D. The effect of mechanical strain on matrix metalloproteinase production by bovine trabecular meshwork cells. Curr. Eye Res. 22:394-397, 2001.
64. Bornstein, P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130:503-506, 1995.
65. Rhee, D.J., Haddadin, R.I., Kang, M.H., and Oh, D.J. Matricellular proteins in the trabecular meshwork. Exp. Eye Res. 88:694-703, 2009.
66. Yan, Q., and Sage, E.H. SPARC, a matricellular glycoprotein with important biological functions. J. Histochem. Cytochem. 47:1495-1506, 1999.
67. Yan, Q., Clark, J.I., and Sage, E.H. Expression and characterization of SPARC in human lens and in the aqueous and vitreous humors. Exp. Eye Res. 71:81-90, 2000.
68. Berryhill, B.L., Kane, B., Stramer, B.M., Fini, M.E., and Hassell, J.R. Increased SPARC accumulation during corneal repair. Exp. Eye Res. 77:85-92, 2003.
69. Kantorow, M., Huang, Q., Yang, X.J., et al. Increased expression of osteonectin/SPARC mRNA and protein in age-related human cataracts and spatial expression in the normal human lens. Mol. Vis. 6:24-29, 2000.
70. Rhee, D.J., Fariss, R.N., Brekken, R., Sage, E.H., and Russell, P. The matricellular protein SPARC is expressed in human trabecular meshwork. Exp. Eye Res. 77:601-607, 2003.
71. Gilbert, R.E., Cox, A.J., Kelly, D.J., et al. Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. Connect. Tissue Res. 40:295-303, 1999.
72. Hiscott, P., Paraoan, L., Choudhary, A., Ordonez, J.L., Al-Khaier, A., and Armstrong, D.J. Thrombospondin 1, thrombospondin 2 and the eye. Prog. Retin. Eye Res. 25:1-18, 2006.
73. Inatani, M., Tanihara, H., Katsuta, H., Honjo, M., Kido, N., and Honda, Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch. Clin. Exp. Ophthalmol. 239:109-113, 2001.
74. Tripathi, R.C., Li, J., Chan, W.F., and Tripathi, B.J. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp. Eye Res. 59:723-727, 1994.
75. Gleizes, P.E., Munger, J.S., Nunes, I., et al. TGF-beta latency: biological significance and mechanisms of activation. Stem Cells 15:190-197, 1997.
76. Annes, J.P., Munger, J.S., and Rifkin, D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 116:217-224, 2003.
77. Schultz-Cherry, S., Lawler, J., and Murphy-Ullrich, J.E. The type 1 repeats of thrombospondin 1 activate latent transforming growth factor-beta. J. Biol. Chem. 269:26783-26788, 1994.
78. Murphy-Ullrich, J.E., and Poczatek, M. Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev. 11:59-69, 2000.
79. Murphy-Ullrich, J.E., Schultz-Cherry, S., and Hook, M. Transforming growth factor-beta complexes with thrombospondin. Mol. Biol. Cell 3:181-188, 1992.
80. Adams, J.C., and Lawler, J. The thrombospondins. Int. J. Biochem. Cell Biol. 36:961-968, 2004.
81. Adams, J.C. Thrombospondins: multifunctional regulators of cell interactions. Annu. Rev. Cell Dev. Biol. 17:25-51, 2001.
82. Schultz-Cherry, S., and Murphy-Ullrich, J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 122:923-932, 1993.
83. Penttinen, R.P., Kobayashi, S., and Bornstein, P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. U S A. 85:1105-1108, 1988.
84. Fleenor, D.L., Shepard, A.R., Hellberg, P.E., Jacobson, N., Pang, I.H., and Clark, A.F. TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 47:226-234, 2006.
85. Flugel-Koch, C., Ohlmann, A., Fuchshofer, R., Welge-Lussen, U., and Tamm, E.R. Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp Eye Res. 79:649-663, 2004.
86. Fuchshofer, R., Yu, A.H., Welge-Lussen, U., and Tamm, E.R. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 48:715-726, 2007.
87. Bornstein, P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest. 107:929-934, 2001.
88. Suzuki, K., Wang, R., Kubota, H., Shibuya, H., Saegusa, J., and Sato, T. Kinetics of biglycan, decorin and thrombospondin-1 in mercuric chloride-induced renal tubulointerstitial fibrosis. Exp. Mol. Pathol. 79:68-73, 2005.
89. Uno, K., Hayashi, H., Kuroki, M., Uchida, H., Yamauchi, Y., and Oshima, K. Thrombospondin-1 accelerates wound healing of corneal epithelia. Biochem. Biophys. Res. Commun. 315:928-934, 2004.
90. Daniel, C., Schaub, K., Amann, K., Lawler, J., and Hugo, C. Thrombospondin-1 is an endogenous activator of TGFbeta in experimental diabetic nephropathy in vivo. Diabetes 56:2982-2989, 2007.
91. Hugo, C. The thrombospondin 1-TGF-beta axis in fibrotic renal disease. Nephrol. Dial. Transplant. 18:1241-1245, 2003.
92. Poczatek, M.H., Hugo, C., Darley-Usmar, V., and Murphy-Ullrich, J.E. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am. J. Pathol. 157:1353-1363, 2000.
93. Crawford, S.E., Stellmach, V., Murphy-Ullrich, J.E., et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 93:1159-1170, 1998.
94. Tripathi, B.J., Tripathi, R.C., Yang, C., Millard, C.B., and Dixit, V.M. Synthesis of a thrombospondin-like cytoadhesion molecule by cells of the trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 32:181-188, 1991.
95. Tripathi, B.J., Li, T., Li, J., Tran, L., and Tripathi, R.C. Age-related changes in trabecular cells in vitro. Exp. Eye Res. 64:57-66, 1997.
96. Liu, X., Wu, Z., Sheibani, N., Brandt, C.R., Polansky, J.R., and Kaufman, P.L. Low dose latrunculin-A inhibits dexamethasone-induced changes in the actin cytoskeleton and alters extracellular matrix protein expression in cultured human trabecular meshwork cells. Exp. Eye Res. 77:181-188, 2003.
97. Hiscott, P., Schlotzer-Schrehardt, U., and Naumann, G.O. Unexpected expression of thrombospondin 1 by corneal and iris fibroblasts in the pseudoexfoliation syndrome. Hum. Pathol. 27:1255-1258, 1996.
98. Tomarev, S.I., Wistow, G., Raymond, V., Dubois, S., and Malyukova, I. Gene expression profile of the human trabecular meshwork: NEIBank sequence tag analysis. Invest. Ophthalmol. Vis. Sci. 44:2588-2596, 2003.
99. Vittal, V., Rose, A., Gregory, K.E., Kelley, M.J., and Acott, T.S. Changes in gene expression by trabecular meshwork cells in response to mechanical stretching. Invest. Ophthalmol. Vis. Sci. 46:2857-2868, 2005.
100. Kirwan, R.P., Fenerty, C.H., Crean, J., Wordinger, R.J., Clark, A.F., and O'Brien, C.J. Influence of cyclical mechanical strain on extracellular matrix gene expression in human lamina cribrosa cells in vitro. Mol. Vis. 11:798-810, 2005.
101. Kirwan, R.P., Leonard, M.O., Murphy, M., Clark, A.F., and O'Brien, C.J. Transforming growth factor-betaregulated gene transcription and protein expression in human GFAP-negative lamina cribrosa cells. Glia 52:309-324, 2005.
102. Chen, C.C., and Lau, L.F. Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 41:771-783, 2009.
103. Leask, A., and Abraham, D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci. 119:4803-4810, 2006.
104. Yeger, H., and Perbal, B. The CCN family of genes: a perspective on CCN biology and therapeutic potential. J. Cell Commun. Signal. 1:159-164, 2007.
105. Brigstock, D.R. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J. Cell Commun. Signal. 4:1-4, 2010.
106. Gupta, S., Clarkson, M.R., Duggan, J., and Brady, H.R. Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int. 58:1389-1399, 2000.
107. Lang, C., Sauter, M., Szalay, G., et al. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirus myocarditis. J. Mol. Med. (Berl). 86:49-60, 2008.
108. Lasky, J.A., Ortiz, L.A., Tonthat, B., et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. Physiol. 275: L365-L371, 1998.
109. Ito, Y., Aten, J., Bende, R.J., et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int. 53:853-861, 1998.
110. Sato, S., Nagaoka, T., Hasegawa, M., et al. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J. Rheumatol. 27:149-154, 2000.
111. Wang, Q., Usinger, W., Nichols, B., et al. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair 4:4, 2011.
112. Weston, B.S., Wahab, N.A., and Mason, R.M. CTGF mediates TGF-beta-induced fibronectin matrix deposition by upregulating active alpha5beta1 integrin in human mesangial cells. J. Am. Soc. Nephrol. 14:601-610, 2003.
113. Crean, J.K., Finlay, D., Murphy, M., et al. The role of p42/ 44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J. Biol. Chem. 277: 44187-44194, 2002.
114. Fuchshofer, R., Birke, M., Welge-Lussen, U., Kook, D., and Lutjen-Drecoll, E. Transforming growth factor-beta 2 modulated extracellular matrix component expression in cultured human optic nerve head astrocytes. Invest. Ophthalmol. Vis. Sci. 46:568-578, 2005.
115. Junglas, B., Yu, A.H., Welge-Lussen, U., Tamm, E.R., and Fuchshofer, R. Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells. Exp. Eye Res. 88:1065-1075, 2009.
116. Cordeiro, M.F., Chang, L., Lim, K.S., et al. Modulating conjunctival wound healing. Eye (Lond). 14 (Pt 3B):536-547, 2000.
117. Picht, G., Welge-Luessen, U., Grehn, F., and Lutjen-Drecoll, E. Transforming growth factor beta 2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development. Graefes Arch. Clin. Exp. Ophthalmol. 239:199-207, 2001.
118. Kottler, U.B., Junemann, A.G., Aigner, T., Zenkel, M., Rummelt, C., and Schlotzer-Schrehardt, U. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp. Eye Res. 80:121-134, 2005.
119. Fuchshofer, R., and Tamm, E.R. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell Tissue Res. 347:279-290, 2011.
120. Fuchshofer, R. The pathogenic role of transforming growth factor-beta2 in glaucomatous damage to the optic nerve head. Exp. Eye Res. 93:165-169, 2010.
121. Schlotzer-Schrehardt, U., Zenkel, M., Kuchle, M., Sakai, L.Y., and Naumann, G.O. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp. Eye Res. 73:765-780, 2001.
122. Schlotzer-Schrehardt, U., and Naumann, G.O. Ocular and systemic pseudoexfoliation syndrome. Am. J. Ophthalmol. 141:921-937, 2006.
123. Schlotzer-Schrehardt, U., von der Mark, K., Sakai, L.Y., and Naumann, G.O. Increased extracellular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest. Ophthalmol. Vis. Sci. 38:970-984, 1997.
124. Ho, S.L., Dogar, G.F., Wang, J., et al. Elevated aqueous humour tissue inhibitor of matrix metalloproteinase-1 and connective tissue growth factor in pseudoexfoliation syndrome. Br. J. Ophthalmol. 89:169-173, 2005.
125. Browne, J.G., Ho, S.L., Kane, R., et al. Connective tissue growth factor is increased in pseudoexfoliation glaucoma. Invest. Ophthalmol. Vis. Sci. 52:3660-3666, 2011.
126. Wallace, D.M., Clark, A.F., Lipson, K., Andrews, D., Crean, J., and O'Brien, C.J. Anti-connective tissue growth factor antibody treatment reduces extracellular matrix production in trabecular meshwork and lamina cribrosa cells. Invest. Ophthalmol. Vis. Sci. 54:7836-7848, 2013.
127. Brekken, R.A., and Sage, E.H. SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol. 19:569-580, 2000.
128. Termine, J.D., Kleinman, H.K., Whitson, S.W., Conn, K.M., McGarvey, M.L., and Martin, G.R. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 26:99-105, 1981.
129. Chlenski, A., and Cohn, S.L. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin. Cell Dev. Biol. 21:55-65, 2010.
130. Abe, K., Hibino, T., Mishima, H., and Shimomura, Y. The cytokine regulation of SPARC production by rabbit corneal epithelial cells and fibroblasts in vitro. Cornea 23:172-179, 2004.
131. Strandjord, T.P., Madtes, D.K., Weiss, D.J., and Sage, E.H. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am. J. Physiol. 277:L628-L635, 1999.
132. Bollinger, K.E., Crabb, J.S., Yuan, X., Putliwala, T., Clark, A.F., and Crabb, J.W. Quantitative proteomics: TGFbeta(2) signaling in trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 52:8287-8294, 2011.
133. Kang, M.H., Oh, D.J., Kang, J.H., and Rhee, D.J. Regulation of SPARC by transforming growth factor beta2 in human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 54:2523-2532, 2013.
134. Taneda, S., Pippin, J.W., Sage, E.H., et al. Amelioration of diabetic nephropathy in SPARC-null mice. J. Am. Soc. Nephrol. 14:968-980, 2003.
135. Ochiai, Y., and Ochiai, H. Higher concentration of transforming growth factor-beta in aqueous humor of glaucomatous eyes and diabetic eyes. Jpn. J. Ophthalmol. 46:249-253, 2002.
136. Norris, R.A., Borg, T.K., Butcher, J.T., Baudino, T.A., Banerjee, I., and Markwald, R.R. Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann. N Y. Acad. Sci. 1123:30-40, 2008.
137. Jackson-Boeters, L., Wen, W., and Hamilton, D.W. Periostin localizes to cells in normal skin, but is associated with the extracellular matrix during wound repair. J. Cell Commun. Signal. 3:125-133, 2009.
138. Norris, R.A., Damon, B., Mironov, V., et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J. Cell Biochem. 101:695-711, 2007.
139. Johnson, E.C., Jia, L., Cepurna, W.O., Doser, T.A., and Morrison, J.C. Global changes in optic nerve head gene expression after exposure to elevated intraocular pressure in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 48:3161-3177, 2007.
140. Wen, W., Chau, E., Jackson-Boeters, L., Elliott, C., Daley, T.D., and Hamilton, D.W. TGF-ss1 and FAK regulate periostin expression in PDL fibroblasts. J. Dent. Res. 89:1439-1443, 2010.
141. Li, G., Oparil, S., Kelpke, S.S., Chen, Y.F., and Thompson, J.A. Fibroblast growth factor receptor-1 signaling induces osteopontin expression and vascular smooth muscle cell-dependent adventitial fibroblast migration in vitro. Circulation 106:854-859, 2002.
142. Horiuchi, K., Amizuka, N., Takeshita, S., et al. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J. Bone Miner. Res. 14:1239-1249, 1999.
143. Sidhu, S.S., Yuan, S., Innes, A.L., et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc. Natl. Acad. Sci. U S A. 107:14170-14175, 2010.
144. Takayama, G., Arima, K., Kanaji, T., et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J. Allergy Clin. Immunol. 118:98-104, 2006.
145. Bornstein, P., Armstrong, L.C., Hankenson, K.D., Kyriakides, T.R., and Yang, Z. Thrombospondin 2, a matricellular protein with diverse functions. Matrix Biol. 19:557-568, 2000.
146. Yang, Z., Kyriakides, T.R., and Bornstein, P. Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol. Biol. Cell 11:3353-3364, 2000.
147. Martinek, N., Shahab, J., Sodek, J., and Ringuette, M. Is SPARC an evolutionarily conserved collagen chaperone? J. Dent. Res. 86:296-305, 2007.
148. Welge-Lussen, U., May, C.A., Neubauer, A.S., and Priglinger, S. Role of tissue growth factors in aqueous humor homeostasis. Curr. Opin. Ophthalmol. 12:94-99, 2001.
149. Tripathi, R.C., Borisuth, N.S., Li, J., and Tripathi, B.J. Growth factors in the aqueous humor and their clinical significance. J. Glaucoma 3:248-258, 1994.
150. Junglas, B., Kuespert, S., Seleem, A.A., et al. Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork. Am. J. Pathol. 180:2386-2403, 2012.
151. Haddadin, R.I., Oh, D.J., Kang, M.H., et al. Thrombospondin-1 (TSP1)-null and TSP2-null mice exhibit lower intraocular pressures. Invest. Ophthalmol. Vis. Sci. 53: 6708-6717, 2012.
152. Rodriguez-Manzaneque, J.C., Lane, T.F., Ortega, M.A., Hynes, R.O., Lawler, J., and Iruela-Arispe, M.L. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U S A. 98:12485-12490, 2001.
153. Kyriakides, T.R., Zhu, Y.H., Yang, Z., Huynh, G., and Bornstein, P. Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am. J. Pathol. 159:1255-1262, 2001.
154. Sakai, K., Sumi, Y., Muramatsu, H., Hata, K., Muramatsu, T., and Ueda, M. Thrombospondin-1 promotes fibroblastmediated collagen gel contraction caused by activation of latent transforming growth factor beta-1. J. Dermatol. Sci. 31:99-109, 2003.
155. Oh, D.J., Kang, M.H., Ooi, Y.H., Choi, K.R., Sage, E.H., and Rhee, D.J. Overexpression of SPARC in human trabecular meshwork increases intraocular pressure and alters extracellular matrix. Invest. Ophthalmol. Vis. Sci. 54:3309-3319, 2013.
156. Rohen, J.W., Lutjen-Drecoll, E., Flugel, C., Meyer, M., and Grierson, I. Ultrastructure of the trabecular meshwork in untreated cases of primary open-angle glaucoma (POAG). Exp. Eye Res. 56:683-692, 1993.
157. Chang, W., Wei, K., Jacobs, S.S., Upadhyay, D., Weill, D., and Rosen, G.D. SPARC suppresses apoptosis of idi-opathic pulmonary fibrosis fibroblasts through constitutive activation of beta-catenin. J. Biol. Chem. 285:8196-8206, 2010.
158. Chua, J., Seet, L.F., Jiang, Y., et al. Increased SPARC expression in primary angle closure glaucoma iris. Mol. Vis. 14:1886-1892, 2008.
159. Haddadin, R.I., Oh, D.J., Kang, M.H., et al. SPARC-null mice exhibit lower intraocular pressures. Invest. Ophthalmol. Vis. Sci. 50:3771-3777, 2009.
160. Bradshaw, A.D., Puolakkainen, P., Dasgupta, J., Davidson, J.M., Wight, T.N., and Helene Sage, E. SPARCnull mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J. Invest. Dermatol. 120:949-955, 2003.
161. Bradshaw, A.D., Reed, M.J., and Sage, E.H. SPARC-null mice exhibit accelerated cutaneous wound closure. J. Histochem. Cytochem. 50:1-10, 2002.
162. Swaminathan, S.S., Oh, D.J., Kang, M.H., Shepard, A.R., Pang, I.H., and Rhee, D.J. TGF-beta2-mediated ocular hypertension is attenuated in SPARC-null mice. Invest. Ophthalmol. Vis. Sci. 55:4084-4097, 2014.